• PDHA1 Acetylation Drives Enzalutamide Resistance via Cupropt

  2026-06-12

  This study identifies PDHA1-driven acetylation signaling as a suppressor of cuproptosis, thereby enabling resistance to enzalutamide in castration-resistant prostate cancer. The results illuminate a metabolic-epigenetic axis that modulates copper-dependent cell death and suggest new intervention points for overcoming drug resistance.

• Genotyping Kit for Target Alleles: Streamlining PCR Across S

  2026-06-12

  The Genotyping Kit for target alleles of insects, tissues, fishes and cells revolutionizes DNA prep by enabling rapid, phenol-free extraction for direct PCR. With a single-tube protocol and optimized master mix, it accelerates molecular biology genotyping research and reduces cross-contamination risks.

• Distinct Dissociation Kinetics of Palonosetron at 5-HT3 Rece

  2026-06-11

  This study reveals that palonosetron—a highly selective 5-HT3 receptor antagonist—exhibits unique, ligand-dependent dissociation kinetics at 5-HT3A and 5-HT3AB receptor subtypes. These kinetic properties, including slow agonist-induced dissociation, help explain palonosetron’s prolonged antiemetic action, with important implications for laboratory and clinical research.

• ATRX-Deficient Glioma Sensitivity to RTK/PDGFR Inhibition

  2026-06-11

  The referenced study discovers that high-grade glioma cells lacking ATRX are significantly more sensitive to receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. This finding highlights the potential for ATRX mutation status to inform targeted therapy strategies and clinical trial design in aggressive gliomas.

• Pyridostigmine Modulates Placental Necroptosis via α7 nAChR

  2026-06-10

  This study demonstrates that pyridostigmine alleviates preeclampsia-like symptoms in rats by inhibiting placental necroptosis through activation of the α7 nicotinic acetylcholine receptor. The findings provide mechanistic insight into non-neuronal cholinergic signaling as a target for managing placental ischemia-driven complications.

• Cimetidine: Bridging H2R Mechanisms and Translational Innova

  2026-06-10

  Explore how Cimetidine’s partial agonist activity and unique pharmacological profile empower next-generation research in gastrointestinal cancers and blood-brain barrier modeling. This article integrates mechanistic insights, experimental validation, and actionable strategies for translational scientists, with a focus on protocol optimization, competitive landscape, and future outlook.

• Tolazoline as a Precision Tool in Airway Cholinergic Neurobi

  2026-06-09

  Explore how Tolazoline, a benchmark α2-adrenergic receptor antagonist, enables advanced dissection of airway cholinergic modulation in vitro. This article delivers a novel, evidence-driven perspective on optimizing assay design and interpretation for airway smooth muscle research.

• A40926: Strategic Leverage in Translational Glycopeptide Res

  2026-06-09

  This thought-leadership article explores A40926’s mechanistic basis as a dalbavancin precursor, its regulatory biosynthesis, and its strategic impact on translational research against multidrug-resistant pathogens. By integrating recent mechanistic insights and workflow guidance, it offers protocol-ready recommendations and a forward-looking perspective for researchers advancing Gram-positive bacterial infection research and antibiotic innovation.

• Thiazovivin: Practical Guide for ROCK Inhibition in Stem Cel

  2026-06-08

  Thiazovivin is a small molecule ROCK inhibitor designed to enhance the efficiency of induced pluripotent stem cell (iPSC) generation and improve survival of human embryonic stem cells (hESCs) after dissociation. It is intended for use in controlled stem cell research workflows and is not suitable for diagnostic or clinical applications.

• Cyclosporin A: Technical Guide for Immunosuppression Researc

  2026-06-08

  Cyclosporin A (cyclic polypeptide, SKU B1922) is a potent cyclophilin inhibitor widely used to study immunosuppression, apoptosis modulation, and mitochondrial function. This product is best suited for cell-based assays, animal models of autoimmune disorders, and mechanistic studies of calcineurin-NFAT signaling; it is not recommended for workflows needing aqueous solubility or long-term solution storage.

• Optimizing Cell Proliferation Assays with CCK-8: Practical W

  2026-06-07

  Unlock highly sensitive cell viability and cytotoxicity data in minutes using the Cell Counting Kit-8 (CCK-8) from APExBIO. This guide translates cutting-edge cancer metastasis research into actionable protocols, troubleshooting insights, and workflow enhancements for maximizing the impact of your WST-8–based assays.

• Açaí Extracts: Hepatocyte Cytotoxicity and Enzyme Induction

  2026-06-06

  This study provides the most comprehensive in vitro evaluation to date of açaí (Euterpe oleracea) extract cytotoxicity and its potential to induce drug-metabolizing enzymes and transporters in human hepatocytes. The findings clarify safety profiles and minimize concerns about major enzyme or transporter induction, offering new evidence for botanical-drug interaction risk assessment.

• Oleic Acid (C18:1(9Z)) in Lipid Metabolism: Protocols & Insi

  2026-06-05

  Oleic Acid (C18:1(9Z)) is a pivotal tool for dissecting lipid metabolism and cell signaling, providing robust models for metabolic and inflammatory research. Recent studies and protocol innovations enable precise control of experimental conditions and improved reproducibility, especially in modeling hepatic lipid dysregulation and inflammation.

• Palonosetron Hydrochloride: Precision 5-HT3 Receptor Antagon

  2026-06-05

  Palonosetron hydrochloride stands apart for its nanomolar potency and allosteric inhibition of 5-HT3 receptors, enabling more robust and prolonged antiemetic responses in preclinical and translational cancer research. This guide delivers actionable protocols, troubleshooting insights, and comparative context to maximize its impact in both receptor and transporter studies.

• Innovative CEC for Precise Drug–α2-Adrenergic Receptor Affin

  2026-06-04

  This study introduces a novel open-tubular capillary electrochromatography (CEC) method for determining binding constants between α2-adrenergic receptors and drug candidates. The approach improves protein economy and analytical throughput, offering practical advancements for drug-receptor affinity screening and pathway research.

454 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page